T cell activating bispecific antigen binding molecules
US12139553B2 · kind B2 · utility
0Cited by
27References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 20, 2022 |
| Grant date | Nov 12, 2024 |
| Priority date | — |
| Expiry date | May 6, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target 511cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.